Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-2121 · 1 trial · 1 indication
DLTs are defined as any of the protocol-specified treatment-emergent adverse events (AEs) with onset within the DLT-evaluation period for the corresponding dose.
DLTs are defined as any of the protocol-specified treatment-emergent adverse events (AEs) with onset within the DLT-evaluation period for the corresponding dose.
| Arm | Type | Description |
|---|---|---|
| Part A: GS-2121 Monotherapy Dose Escalation | EXPERIMENTAL | Participants will receive escalating doses of GS-2121 monotherapy until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol. |
| Part B: GS-2121 Monotherapy Dose Expansion | EXPERIMENTAL | Participants with selected indications will receive GS-2121 monotherapy at the recommended dose for expansion. |
| Part C: Combination Dose Escalation of GS-2121 with Zimberelimab | EXPERIMENTAL | Participants will receive escalating doses of GS-2121 in combination with zimberelimab until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol. |
| Part D: Combination Dose Expansion of GS-2121 with Zimberelimab | EXPERIMENTAL | Participants with selected indications will receive GS-2121 at the recommended dose for expansion in combination with zimberelimab. |
| Name | Type | Description |
|---|---|---|
| GS-2121 | DRUG | Tablet administered orally |
| Zimberelimab | DRUG | Administered intravenously |
Key Inclusion Criteria: * Participants diagnosed with histologically or cytologically confirmed advanced solid tumors who have progressed despite standard therapy, are intolerant to standard therapy, or are ineligible for standard therapy. * Measurable disease per Response Evaluation Criteria in So...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GS-2121 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
GS-2121 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is sponsoring a Phase 1 clinical trial to evaluate the drug in adults with advanced solid tumors.
GS-2121 is in Phase 1 clinical development. It is an investigational drug, meaning it is not yet approved for any use. The ongoing Phase 1 trial is recruiting participants to study the drug given alone or in combination in adults with advanced solid tumors.
GS-2121 is being studied in one active Phase 1 clinical trial with the identifier NCT06532565. This trial is titled 'Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors' and is currently recruiting participants in the United States and Canada.
No alternative names for GS-2121 have been reported. The drug is identified solely by its code name GS-2121 in clinical trial records and by its developer, Gilead Sciences.